Nano Pharmaceuticals
Market Cap
₹189 ₹189 Cr.
P/E
0.00
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.52
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
22.91 %
Institutions
Institutions
-
Market cap
Market cap
189 Cr
No. of Shareholders
No. of Shareholders
8,756
OPM (%)
OPM (%)
-0.40 %
PE
PE
-
Prom Holding
Prom Holding
50.92 %
ROCE (%)
ROCE (%)
-5.64
ROE (%)
ROE (%)
-
Sales
Sales
190 Cr
  • Natural Capsules
  • Brooks Laboratories
  • Accretion Nutraveda
Last updated on 3 Sep 2026
  • Natural Capsules makes gelatin and vegetarian HPMC capsules with a small steroidal API arm; exports near 29% of sales.
  • Q1 sales understated as ERP fault pushed five days' dispatches into Q2.
  • Capsules fund earnings while API bleeds; gelatin pass-through held per management, HPMC US sales absent.
  • Building toward steroidal API scale via backward integration, PLI and Fermbox CMO; HPMC flexed to gelatin; ₹25-30Cr clean-room build underway.
  • API build soaks capital while cash stays thin.
  • Near-term rests on API losses narrowing; FY27 revenue guided ₹274Cr with API margin assumed near breakeven.
  • Credibility thin after repeated API, HPMC and revenue-guide misses.
  • Promoter preferential issue 9 Sep 2026 EGM
    ₹10.01Cr working-capital raise; Mundra to 10.61% if fully converted.
  • HPMC line deployment Sep 2026
    second line shifts to gelatin; US revenue and 18% margin hinge on approvals.
  • Prednisolone integration and PLI Sep 2026, PLI Q3-Q4FY27
    first backward-integrated batch enables eligible volumes and incentive receipts.
  • WHO-GMP audit and approvals by end-Q2FY27
    outcome gates regulated-market customers and API breakeven.
  • Fermbox CMO ramp Balance FY27
    ₹14Cr guided FY27 CMO revenue proves share economics.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
138
52W Range
High
296
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

5 Yes

Positive for this company

2 Neutral

Neutral for this company

8 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Asset Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Natural Capsules Ltd. Business

Natural Capsules Limited is a public limited company with modern manufacturing plants in Bangalore and Pondicherry. It specializes in producing hard gelatin and cellulose capsule shells, meeting cGMP and cGLP standards, and providing turnkey solutions.

Natural Capsules major competitors are Brooks Laboratories, Accretion Nutraveda, Chemkart India, Bio Medica Labs., Oxygenta Pharma, Coral Laboratories, Smruthi Organics.
Market Cap of Natural Capsules is ₹196 Crs.
While the median market cap of its peers are ₹198 Crs.

Natural Capsules seems to be less financially stable compared to its competitors.
Altman Z score of Natural Capsules is 1.58 and is ranked 7 out of its 8 competitors.

Company Filing

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material